Obermatt
See Similar Stocks →

Certara

NSQ:CERT · US15687V1098
Health Care TechnologyMedium

360

45
EV / EBIT72
Price / Owner Earnings49
Owner Earnings Yield82
Dividend Yield1
Price/Sales96
EV / Gross Profit61
Price/Book76
Return on Capital26
Cash Return on Capital56
Return on Equity25
EBIT Margin28
Gross Profitability24
Accruals78
Owner Earnings Margin82
Sales growth34
Profit Growth87
Long-Term EPS Growth45
Owner Earnings Growth26
Reinvestment7
Price momentum8
Debt load28
Refinancing33
Debt Payback38
Liquidity90
Analyst ratings7
Opinion Changes26
Price Target Upside54
Market mood37
Value Creation8/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Certara clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryHealth Care Technology
SizeMedium
TypePublic Company
ExchangeNASDAQGS
Founded2017
Employees1,172
Websitecertara.com
ISINUS15687V1098
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Machine LearningData IntegrationPharmacovigilanceHealth DiagnosticsArtificial IntelligencePredictive AnalyticsSoftware DevelopmentSimulationBiotechnologyPharmaceutical

Description

Certara, Inc. (‘the company’) provides biosimulation technology and solutions for using Model-Informed Drug Development (‘MIDD’) in the global biopharmaceutical industry. MIDD is an approach that utilizes biological and statistical models derived fr…

Analysis

Middle-of-the-road

Certara, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

The price is attractive. You pay 13.9× its owner earnings: the cash an owner could take out each year, which is in the historically attractive zone. At today's price, the market is assuming roughly 1% yearly growth; analysts expect 8%. The price, in other words, assumes less than the experts do.

The trajectory is tepid and the balance sheet is adequate. The company scores 8/20 on our value-creation score: creating some value.

What to watch: A large part of the company's book value is the price paid for past acquisitions. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
21
2023202420252026

All-time high

51

Jan 2023

All-time low

19

Jan 2025

Average rank

31

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
96
29
15
18
Price/Earnings
14
51
53
45
Price/Book
76
74
60
47
Dividend Yield
1
1
1
1
Value (overall)
85
35
27
27

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Certara with its peers
Schrödinger
NSQ:SDGR
14
CountryUSA
IndustryHealth Care Technology
SizeMedium
Full Stock Analysis →
Inotiv
NAQ:NOTV
16
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
Aurinia Pharmaceuticals
NMQ:AUPH
85
CountryCanada
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Metagenomi Therapeutics
NSQ:MGX
24
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Medpaces
NSQ:MEDP
96
CountryUSA
IndustryLife Sciences Tools & Services
SizeLarge
Full Stock Analysis →
Charles River Laboratories
NYQ:CRL
17
CountryUSA
IndustryLife Sciences Tools & Services
SizeX-Large
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →